Prem Rout - 29 Jun 2026
Drug Discovery Services Market to Reach US$67.3 Billion by 2035: How AI, CROs, and Biotech Are Reshaping Pharma R&D
The global drug discovery services market is expected to grow to US$67.3 billion by 2035. Discover how AI, CROs, biologics, and outsourcing are transforming pharmaceutical R&D and creating new career opportunities.
Prem Rout - 25 Jun 2026
EC Approves Padcev + Keytruda for Resectable Muscle-Invasive Bladder Cancer in Europe
The European Commission has approved Padcev plus Keytruda as perioperative treatment for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy.
Roche Launches AXELIOS 1: How SBX Technology Could Transform DNA Sequencing and Genomics Research
Roche has launched AXELIOS 1, a next-generation DNA sequencing platform powered by SBX technology. Discover its features, how it compares to existing sequencing systems, and what it means for genomics, clinical research, and pharma careers.
Drug Discovery Services Market to Reach US$67.3 Billion by 2035: How AI, CROs, and Biotech Are Reshaping Pharma R&D
The global drug discovery services market is expected to grow to US$67.3 billion by 2035. Discover how AI, CROs, biologics, and outsourcing are transforming pharmaceutical R&D and creating new career opportunities.
EC Approves Padcev + Keytruda for Resectable Muscle-Invasive Bladder Cancer in Europe
The European Commission has approved Padcev plus Keytruda as perioperative treatment for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy.
AbbVie Gets European Commission Approval for Skyrizi in Children With Plaque Psoriasis
AbbVie has received European Commission approval for Skyrizi (risankizumab) to treat children and adolescents aged six years and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.
-1782201163918-947677154.jpg)
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion: A Major Immunology and Asthma Pipeline Bet
AbbVie plans to acquire Apogee Therapeutics for approximately $10.9 billion, strengthening its immunology pipeline in atopic dermatitis and asthma through long-acting antibody candidates including zumilokibart and APG273.
Johnson & Johnson MEMBRANE Trial Shows Positive Results for Chronic Subdural Hematoma Treatment
Johnson & Johnson’s MEMBRANE trial found that middle meningeal artery embolization with TRUFILL n-BCA plus standard care reduced chronic subdural hematoma recurrence and re-intervention compared with standard care alone.
-1781934369317-941754662.jpg)
Chiesi Showcases New Lipodystrophy Research at ENDO 2026: Expanding Understanding of Rare Metabolic Disorders
Chiesi Global Rare Diseases presented new metreleptin research at ENDO 2026, highlighting treatment outcomes, mental health challenges, and emerging care approaches for patients living with lipodystrophy.
The Rise of AI Knowledge Graphs in Pharma R&D: Why Connected Intelligence Is Becoming the Industry's Biggest Competitive Advantage
AI knowledge graphs are transforming pharmaceutical R&D by connecting scientific, clinical, regulatory, and real-world data. Discover how pharma companies are using AI-powered knowledge ecosystems to accelerate drug discovery, improve decision-making, and create future-ready careers.
Sun Pharma's Osteoarthritis Drug Receives USFDA Fast Track Status: A Major Innovation Milestone for Indian Pharma
Sun Pharma and Moebius Medical have received USFDA Fast Track designation for MM-II, a novel non-opioid treatment for osteoarthritis knee pain. Explore the significance, industry impact, and career opportunities arising from this breakthrough.
Alembic Pharma Secures USFDA Approval for Generic Drug: What It Means for Growth, Innovation, and Pharma Careers
Alembic Pharma has received USFDA approval for a generic drug, strengthening its position in the U.S. market. Discover the business impact, industry significance, and career opportunities this regulatory milestone creates.
